This dual-targeting method may effectively manage CTCL by decreasing angiogenesis, migration, and tumor growth through the downregulation of VEGF-A, reduction in HDAC activity, and inhibition of JAK/STAT, PI3K/AKT, and ERK signaling pathways [56]. This evidence concerns the gene AKT1 and neoplasm.